- Dana-Farber investigators receive $13.3 million in funding to study whether some groups of patients with DCIS who do not benefit from standard treatment, could be effectively managed with surveillance alone.
- Dana-Farber Cancer Institute today announced an immuno-oncology collaboration with potential applicability in a wide range of oncology indications with Array BioPharma.
Tags: Partnerships, Immunotherapy
- Researchers found a way of differentiating angiocentric gliomas from other low-grade pediatric brain tumors and developed a pathological test that will help children avoid unnecessary and potentially damaging additional therapies.
Tags: BasicResearch, ChildhoodCancer, BrainTumors
- Clinical genomic sequencing is feasible in pediatric oncology and can be used to recommend therapy or pinpoint diagnosis in children with solid tumors according to research led by Dana-Farber/Boston Children's Cancer and Blood Disorders Center. The findings, published in JAMA Oncology, represent a significant step in making precision medicine available to children with cancer.
Tags: ChildhoodCancer, TargetedTherapy, Genetics
- Research by Dana-Farber scientists reveals genes with monoallelic expression are an important source of genetic diversity among people and also may help explain the genetic variation among cancer cells in a tumor.
Tags: BasicResearch, Genetics
- Three Dana-Farber researchers, writing in a special issue of JAMA published today, make the case for policies and practices that give terminally ill patients more control over how and where they will die.
Tags: ColonCancer, EndOfLife, LungCancer
- Dana-Farber researchers uncover first potential targeted drug for triple-negative breast cancer as well as vulnerability that could be exploited to slow or prevent the development of resistance to BET-inhibiting drugs.
Tags: BasicResearch, BreastCancer
Showing 1-10 of 656 items